Effects of captopril once daily on blood pressure and angiotensin converting enzyme in hypertensive patients. 1986

F J Rodriguez, and V Gil, and M del Carmen Beneyto, and E Lopez-Vidriero
Section of Hypertension, Provincial Hospital, 28007 Madrid, Spain.

An investigation of the therapeutic effect of a once daily dose of captopril was carried out on 19 patients with essential hypertension. Captopril was administered at a dose of 50 mg/day for 2 weeks. If blood pressure was not reduced to less than 160/95 mm Hg in that time, the dose was increased to 100 mg/day for a further 2 weeks (5 patients). If blood pressure remained high, 50 mg chlorthalidone/day was added (4 patients). Only 1 patient was not controlled. The drugs were administered in the morning. Blood pressure and serum angiotensin converting enzyme activity (SACE) were measured 24 hours after the last dose, and patients were followed up to 3 months. The basal SACE decreased 24 hours after the first captopril dose but 3 months later, when blood pressure was controlled, the mean level was back to baseline values. Our results show that once-daily captopril is efficacious in hypertension and its hypotensive effect appears to be independent of ACE inhibition.

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D007703 Peptidyl-Dipeptidase A A peptidyl-dipeptidase that catalyzes the release of a C-terminal dipeptide, oligopeptide-|-Xaa-Yaa, when Xaa is not Pro, and Yaa is neither Asp nor Glu. Thus, conversion of ANGIOTENSIN I to ANGIOTENSIN II, with increase in vasoconstrictor activity, but no action on angiotensin II. It is also able to inactivate BRADYKININ, a potent vasodilator; and has a glycosidase activity which releases GPI-anchored proteins from the membrane by cleaving the mannose linkage in the GPI moiety. (From https://www.uniprot.org April 15, 2020). ACE1 Angiotensin-Converting Enzyme 1,ACE1 Protein,Angiotensin Converting Enzyme,Angiotensin Converting Enzyme 1,Antigens, CD143,CD143 Antigens,Dipeptidyl Carboxypeptidase I,Kininase II,Peptidase P,Angiotensin I-Converting Enzyme,Carboxycathepsin,Dipeptidyl Peptidase A,Kininase A,ACE1 Angiotensin Converting Enzyme 1,Angiotensin I Converting Enzyme,Carboxypeptidase I, Dipeptidyl,Peptidyl Dipeptidase A
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D001794 Blood Pressure PRESSURE of the BLOOD on the ARTERIES and other BLOOD VESSELS. Systolic Pressure,Diastolic Pressure,Pulse Pressure,Pressure, Blood,Pressure, Diastolic,Pressure, Pulse,Pressure, Systolic,Pressures, Systolic
D002216 Captopril A potent and specific inhibitor of PEPTIDYL-DIPEPTIDASE A. It blocks the conversion of ANGIOTENSIN I to ANGIOTENSIN II, a vasoconstrictor and important regulator of arterial blood pressure. Captopril acts to suppress the RENIN-ANGIOTENSIN SYSTEM and inhibits pressure responses to exogenous angiotensin. (S)-1-(3-Mercapto-2-methyl-1-oxopropyl)-L-proline,Capoten,Lopirin,SQ-14,225,SQ-14,534,SQ-14225,SQ-14534,SQ 14,225,SQ 14,534,SQ 14225,SQ 14534,SQ14,225,SQ14,534,SQ14225,SQ14534
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly

Related Publications

F J Rodriguez, and V Gil, and M del Carmen Beneyto, and E Lopez-Vidriero
February 1996, The Journal of the Association of Physicians of India,
F J Rodriguez, and V Gil, and M del Carmen Beneyto, and E Lopez-Vidriero
April 1982, Nihon Jinzo Gakkai shi,
F J Rodriguez, and V Gil, and M del Carmen Beneyto, and E Lopez-Vidriero
February 1980, British medical journal,
F J Rodriguez, and V Gil, and M del Carmen Beneyto, and E Lopez-Vidriero
June 1989, Journal of human hypertension,
F J Rodriguez, and V Gil, and M del Carmen Beneyto, and E Lopez-Vidriero
August 2021, Cureus,
F J Rodriguez, and V Gil, and M del Carmen Beneyto, and E Lopez-Vidriero
February 2003, American journal of hypertension,
F J Rodriguez, and V Gil, and M del Carmen Beneyto, and E Lopez-Vidriero
January 1984, Hypertension (Dallas, Tex. : 1979),
F J Rodriguez, and V Gil, and M del Carmen Beneyto, and E Lopez-Vidriero
February 1981, Endocrinology,
F J Rodriguez, and V Gil, and M del Carmen Beneyto, and E Lopez-Vidriero
July 1981, Kokyu to junkan. Respiration & circulation,
F J Rodriguez, and V Gil, and M del Carmen Beneyto, and E Lopez-Vidriero
September 1989, Journal of hypertension. Supplement : official journal of the International Society of Hypertension,
Copied contents to your clipboard!